Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18663285 | 0.88 | CCNC (0.32) | ALDH1A1MAPTHPGDKDM4ELMNA | |
| SCHEMBL18663279 | 0.82 | PDE3B (0.33) | ADORA3GRM6ALDH1A1MAPTLMNA | |
| SCHEMBL19690388 | 0.81 | ADORA3 (0.32) | ADORA3ALDH1A1MAPTHPGDTDP1 | |
| SCHEMBL18663328 | 0.80 | SMN1; SMN2 (0.40) | ALDH1A1MAPTHPGDNPC1LMNA | |
| SCHEMBL18663413 | 0.77 | TSHR (0.34) | ALDH1A1MAPTTDP1 | |
| SCHEMBL18663372 | 0.76 | MAPT (0.39) | ALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL19690581 | 0.71 | MTNR1A (0.36) | ALDH1A1MAPTHPGDNPC1LMNA | |
| SCHEMBL19690582 | 0.70 | CCNC (0.34) | ALDH1A1MAPTHPGDKDM4ELMNA | |
| SCHEMBL18663361 | 0.69 | ADORA3 (0.33) | ADORA3GRM6ALDH1A1MAPTHPGD | |
| SCHEMBL18663272 | 0.66 | FPR1 (0.35) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088642-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST CONTAINING CATALYST COMPONENT AND USE THEREOF | BEIJING LIHE TECH LTD (CN) | 2017-03-30 | — | — | US | claimed |
| US-20170088642-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST CONTAINING CATALYST COMPONENT AND USE THEREOF | BEIJING LIHE TECH LTD (CN) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088642-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST CONTAINING CATALYST COMPONENT AND USE THEREOF | TEC, DGAT2, MOGAT2 | ADORA3 4824/4885GRM6 2858/4885ALDH1A1 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.